About Absci Corporation
https://www.absci.comAbsci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process.
CEO
Sean McClain
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 91
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
FMR LLC
Shares:22.08M
Value:$73.98M
ARK INVESTMENT MANAGEMENT LLC
Shares:12.16M
Value:$40.75M
BLACKROCK, INC.
Shares:10.58M
Value:$35.45M
Summary
Showing Top 3 of 153
About Absci Corporation
https://www.absci.comAbsci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $378K ▼ | $30.53M ▲ | $-28.71M ▲ | -7.59K% ▼ | $-0.2 ▲ | $-25.71M ▲ |
| Q2-2025 | $593K ▼ | $11.53M ▼ | $-30.57M ▼ | -5.15K% ▼ | $-0.24 ▼ | $-28.39M ▼ |
| Q1-2025 | $1.18M ▲ | $12.54M ▼ | $-26.35M ▲ | -2.23K% ▲ | $-0.21 ▲ | $-24.66M ▲ |
| Q4-2024 | $665K ▼ | $13.46M ▼ | $-28.98M ▼ | -4.36K% ▼ | $-0.25 ▼ | $-25.14M ▼ |
| Q3-2024 | $1.7M | $27.24M | $-27.4M | -1.61K% | $-0.24 | $-23.88M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $152.47M ▲ | $244.99M ▲ | $34.65M ▼ | $210.34M ▲ |
| Q2-2025 | $117.46M ▼ | $209.89M ▼ | $36.52M ▲ | $173.37M ▼ |
| Q1-2025 | $133.98M ▲ | $232.45M ▲ | $33.65M ▼ | $198.8M ▲ |
| Q4-2024 | $112.42M ▼ | $213.61M ▼ | $34.48M ▲ | $179.13M ▼ |
| Q3-2024 | $127.07M | $235.23M | $33.9M | $201.34M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-28.71M ▲ | $-25.03M ▼ | $-63.7M ▼ | $60.32M ▲ | $-28.41M ▼ | $-25.99M ▼ |
| Q2-2025 | $-30.57M ▼ | $-16.87M ▲ | $9.04M ▲ | $-1M ▼ | $-8.84M ▼ | $-17.1M ▲ |
| Q1-2025 | $-26.35M ▲ | $-21.84M ▼ | $-15.04M ▼ | $42.79M ▲ | $5.91M ▲ | $-21.86M ▼ |
| Q4-2024 | $-28.98M ▼ | $-16.96M ▲ | $19.04M ▲ | $986K ▲ | $3.06M ▲ | $-16.99M ▲ |
| Q3-2024 | $-27.4M | $-20.73M | $14.81M | $490K | $-5.45M | $-20.78M |
CEO
Sean McClain
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 91
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
FMR LLC
Shares:22.08M
Value:$73.98M
ARK INVESTMENT MANAGEMENT LLC
Shares:12.16M
Value:$40.75M
BLACKROCK, INC.
Shares:10.58M
Value:$35.45M
Summary
Showing Top 3 of 153